MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

Metsera (NASDAQ:MTSR ... If it can prove to achieve comparable weight loss to other drugs but offer a far more convenient once-monthly dosing option with its MET-097i drug, plus tolerable safety ...

In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection led to 22% weight loss measured at 36 weeks. Last month, Metsera raised $275 million from its ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing ...

About Metsera Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based ...

Metsera, Inc. (NASDAQ ... the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners ...

Oral peptide platform development on track with weight loss and tolerability data for MET-224 o expected ... for less frequent dosing and improved tolerability. In February, Metsera completed an IPO, ...